Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02064829 · ClinicalTrials.gov registry record · NA
Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast Cancer
A NA study, sponsored by Sorrento Therapeutics.
- Completed
- Registry status
- NA
- Development phase
- 111
- Enrollment target
NCT02064829 is a NA study that has completed, run by Sorrento Therapeutics. The registered enrollment target is 111 participants.
The verdict
NCT02064829, a NA study, has completed, sponsored by Sorrento Therapeutics.
- COMPLETED
- Registry status
- NA
- Development phase
- 111 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate bioequivalence of IG-001 versus nab-paclitaxel in female patients with metastatic or locally recurrent breast cancer. In addition, the study will compare the safety and tolerance of IG-001 and nab-paclitaxel during the bioequivalence 2-period crossover portion of the study. The study will also evaluate the long-term safety of IG-001 over repeated cycles, up to 4 additional cycles of administration.
Interventions
- DRUG Nab-paclitaxel
- DRUG IG-001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2014-03 |
| Est. Completion | 2015-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02064829
The ClinicalTrials.gov registry entry for NCT02064829 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sorrento Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nab-paclitaxel is the first listed.
NCT02064829 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02064829 about?
NCT02064829 is a clinical study titled "Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast Cancer". The purpose of this study is to demonstrate bioequivalence of IG-001 versus nab-paclitaxel in female patients with metastatic or locally recurrent breast cancer. In addition, the study will compare the safety and tolerance of IG-001 and nab-paclitaxel during the bioequivalence 2-period crossover por...
What is the current status of trial NCT02064829?
This trial is currently completed. It is a NA study. The enrollment target is 111 participants. The study started on 2014-03. Estimated completion is 2015-07.
What interventions are being tested in trial NCT02064829?
The interventions under investigation include: Nab-paclitaxel (DRUG), IG-001 (DRUG).
Who is sponsoring clinical trial NCT02064829?
This trial is sponsored by Sorrento Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.